Open Orphan has announced that its subsidiary hVIVO has signed a £10.4 million contract with an unnamed major global pharmaceutical client, to manufacturing a new batch of H1N1 flu challenge virus, and to conduct a human challenge trial to test the client’s antiviral product.
Open Orphan – a specialists in testing infectious and respiratory disease products using human challenge clinical trials – has announced that its subsidiary, hVIVO, has signed a £6.2m contract with a US-based biotechnology company to test its antiviral candidate.
Under the terms of this agreement, the company researchers will carry out a double-blind, placebo, controlled assessment of the drug, which means one cohort will receive the active treatment, while the other half will be administered a substance with no medicinal value.
Open Orphan has been appointed by an unnamed existing “big pharma” client to host a Phase II field study of a potential vaccine for respiratory syncytial virus (RSV).
Open Orphan has announced that they are progressing with their government-backed COVID-19 vaccine human challenge study.nThe company has signed a £5.7 million contract for a challenge study for a biotech company developing an anti-flu treatment.